Lymphoma, Non-Hodgkin
318
27
52
176
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
93 trials with published results (29%)
Research Maturity
176 completed trials (55% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.4%
49 terminated out of 318 trials
78.2%
-8.3% vs benchmark
8%
27 trials in Phase 3/4
53%
93 of 176 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 176 completed trials
Clinical Trials (318)
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
Epcoritamab-CAR T Cells for Large B-cell Lymphomas